Tinengotinib
Based on 1 Customer Validation
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.57%
- No. CAS: 2230490-29-4
- Fòrmula: C20H19ClN6O
- Peso molecular:394.86
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-10126
Barasertib-HQPAAurora B Inhibitor -
HY-114258
LY3295668Aurora A Kinase Inhibitor -
HY-50904
NintedanibPDGFR/VEGFR/FGFR Inhibitor -
HY-112355
Aurora kinase inhibitor-2Aurora Kinase Inhibitor -
HY-137377
TAS-119Aurora A Inhibitor -
HY-50904R
Nintedanib (Standard)PDGFR/VEGFR/FGFR Inhibitor -
HY-12201
TAK-901 -
HY-10558
CYC-116aurora A/B Inhibitor -
HY-13737
R1530Mitosis/Angiogenesis Inhibitor -
HY-10128
ZM-447439Aurora A/B Inhibitor -
HY-13252
MK-5108Aurora Kinase Inhibitor -
HY-10178
PHA-680632Aurora Kinase Inhibitor
Ver todos los productos específicos de isoformas Aurora Kinase
MoreVer todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
IC50 & Target
|
FGFR1 |
FGFR2 |
FGFR3 |
Aurora A |
Aurora B |
In Vitro
Tinengotinib (0.1-10 μM; 72 h) inhibits the proliferation of triple-negative breast cancer (TNBC) cell lines (MDA-MB-468, HCC1806) and gallbladder cancer cell lines (NOZ, GBC-SD) in a concentration-dependent manner, induces G2/M cell cycle arrest and apoptosis, and downregulates the expression of proteins related to the Aurora A/B, FGFR1/2/3 and JNK/JUN signaling pathways[1].
Tinengotinib (1 μM; 48 h) inhibits VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVEC) cells, reduces the expression of angiogenesis-related proteins, and inhibits in vitro angiogenesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468, HCC1806 (TNBC); NOZ, GBC-SD (gallbladder cancer)
-
Concentration:0.1, 0.5, 1, 5, 10 μM
-
Incubation Time:72 hours
-
Result:Significantly reduced cell viability in a dose-dependent manner, with IC50 values of 0.73 μM (MDA-MB-468), 0.42 μM (HCC1806), 0.076 μM (NOZ), and 0.18 μM (GBC-SD).
Resulted a 60-80% reduction in colony number at 5 μM compared to control.
In Vivo
Tinengotinib (15 mg/kg; oral gavage; once daily; 4 weeks) reduces tumor volume and inhibits expression of the angiogenesis marker CD34 in patient-derived gallbladder cancer xenograft (PDX) mouse models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 20-22 g, 6 weeks old) with subcutaneous HCC1806 triple-negative breast cancer (TNBC) xenografts[1]
-
Dosage:15 mg/kg
-
Administration:Oral gavage, daily, for 2-3 weeks
-
Result:Significantly inhibited tumor growth, with a dose-dependent reduction in tumor volume and weight.
Downregulated the proliferation marker Ki67 in tumor tissues in Immunohistochemistry (IHC) staining assay.
Showed a rapid distribution to tumor sites, with peak concentrations at 7 hours post-dosing and no significant systemic toxicity observed in Pharmacokinetic analysis.
-
Animal Model:BALB/c nude mice (male, 25-30 g, 6 weeks old) with patient-derived gallbladder cancer (GBC) xenografts (PDX)[2]
-
Dosage:15 mg/kg
-
Administration:Oral gavage, daily, for 4 weeks
-
Result:Led to a significant decrease in tumor volume and weight compared to the control group.
Reduced expression of the angiogenesis marker CD34, suggesting inhibition of tumor vascularization in IHC staining assay.
No significant changes in mouse body weight or organ toxicity were observed during the treatment period.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 2230490-29-4
-
Appearance Solid
-
Peso molecular 394.86
-
Fòrmula C20H19ClN6O
-
Color Light yellow to yellow
-
SMILES
ClC1=C(C2=NC3=C(C)NN=C3NC4=C2C=NC(N5CCOCC5)=C4)C=CC=C1
-
Synonyms
TT 00420
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (126.63 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Peng P, et al. Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer. Mol Cancer Ther. 2023 Feb 1;22(2):205-214. [Content Brief]
[2]. Miao H, et al. Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway. Cell Oncol (Dordr). 2022 Aug;45(4):689-708. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5325 mL | 12.6627 mL | 25.3254 mL | 63.3136 mL |
| 5 mM | 0.5065 mL | 2.5325 mL | 5.0651 mL | 12.6627 mL | |
| 10 mM | 0.2533 mL | 1.2663 mL | 2.5325 mL | 6.3314 mL | |
| 15 mM | 0.1688 mL | 0.8442 mL | 1.6884 mL | 4.2209 mL | |
| 20 mM | 0.1266 mL | 0.6331 mL | 1.2663 mL | 3.1657 mL | |
| 25 mM | 0.1013 mL | 0.5065 mL | 1.0130 mL | 2.5325 mL | |
| 30 mM | 0.0844 mL | 0.4221 mL | 0.8442 mL | 2.1105 mL | |
| 40 mM | 0.0633 mL | 0.3166 mL | 0.6331 mL | 1.5828 mL | |
| 50 mM | 0.0507 mL | 0.2533 mL | 0.5065 mL | 1.2663 mL | |
| 60 mM | 0.0422 mL | 0.2110 mL | 0.4221 mL | 1.0552 mL | |
| 80 mM | 0.0317 mL | 0.1583 mL | 0.3166 mL | 0.7914 mL | |
| 100 mM | 0.0253 mL | 0.1266 mL | 0.2533 mL | 0.6331 mL |
Tinengotinib Related Classifications
HY-145601 Related Classifications
Powered by Bioz